Zymeworks To Acquire Theravance Biopharma For $929 Mln In Cash Deal, TBPH Stock Down In Pre-Market

rttnews.com · 2026-06-29

Monday, Zymeworks Inc. (ZYME) agreed to acquire Theravance Biopharma, Inc. (TBPH) in an all-cash deal valued at approximately $929 million, offering $17.00 per share.

TickrTrends take: Theravance Biopharma's acquisition at a cash price of 929 million dollars provides a concrete valuation benchmark for the company, which TickrTrends is currently assessing as it awaits full valuation analysis. For investors focused on valuation metrics, this transaction establishes a defined exit price that can be compared against TBPH's historical trading valuations and peer multiples in the Healthcare sector. The pre-market stock decline following the announcement suggests market participants are evaluating whether the acquisition price reflects fair value relative to the company's underlying assets and pipeline prospects.

Read the full story at rttnews.com →